Page 1364 - Williams Hematology ( PDFDrive )

1338 Part X: Malignant Myeloid Diseases Chapter 86: Primary Myelofibrosis 1339

470. Papageorgiou SG, Castleton A, Bloor A, Kottaridis PD: Allogeneic stem cell transplan- 490. Campbell PJ, Griesshammer M, Döhner K, et al: V617F mutation in JAK2 is associated
tation as treatment for myelofibrosis. Bone Marrow Transplant 38:721, 2006. with poorer survival in idiopathic myelofibrosis. Blood 107:2098, 2006.
471. Barosi G, Bacigalupo A: Allogeneic hematopoietic stem cell transplantation for myelo- 491. Cervantes F, Dupriez B, Pereira A, et al: A new prognostic scoring system for primary
fibrosis. Curr Opin Hematol 13:74, 2006. myelofibrosis based on a study of the International Working Group for Myelofibrosis
472. Kerbauy DM, Gooley TA, Sale GE, et al: Hematopoietic cell transplantation as curative Research and Treatment. Blood 113:2895, 2009.
therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential throm- 492. Rozman C, Giralt M, Feliu E, et al: Life expectancy of patients with chronic non-
bocythemia. Biol Blood Marrow Transplant 13:355, 2007. leukemic myeloproliferative disorders. Cancer 67:2658, 1991.
473. Rondelli D: Allogeneic hematopoietic stem cell transplantation for myelofibrosis. 493. Mascarenhas J, Hoffman R: A comprehensive review and analysis of the effect of ruxoli-
Haematologica 93:1449, 2008. tinib therapy on the survival of patients with myelofibrosis. Blood 121:4832, 2013.
474. Li Z, Deeg HJ: Pros and cons of splenectomy in patients with myelofibrosis undergoing 494. Passamonti F, Maffioli M, Cervantes F, et al: Impact of ruxolitinib on the natural history
stem cell transplantation. Leukemia 15:465, 2001. of primary myelofibrosis: A comparison of the DIPSS and the COMFORT-2 cohorts.
475. Byrne JL, Beshti H, Clark D, et al: Induction of remission after donor leucocyte infusion Blood 123:1833, 2014.
for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic trans- 495. Silverstein MN, Brown AL, Linman JW: Idiopathic myeloid metaplasia, its evolution
plantation: Evidence for a “graft vs. myelofibrosis” effect. Br J Haematol 108:430, 2000. into acute leukemia. Arch Intern Med 132:709, 1973.
476. Cervantes F, Rovira M, Urbano-Ispizua A, et al: Complete remission of idiopathic mye- 496. Marcus RE, Hibbin JA, Matutes E, et al: Megakaryoblastic transformation of myelofi-
lofibrosis following donor lymphocyte infusion after failure of allogeneic transplanta- brosis with expression of the c-sis oncogene. Am J Hematol 36:186, 1986.
tion: Demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplant 497. Hernandez JM, SanMiguel JF, Gonzalez M, et al: Development of acute leukaemia after
26:697, 2000. idiopathic myelofibrosis. J Clin Pathol 45:427, 1992.
477. Kröger N, Badbaran A, Holler E, et al: Monitoring of the JAK2-V617F mutation by 498. Palphilon DH, Creamer P, Keeling DH, et al: Restoration of active haemopoiesis in
highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in a patient with myelofibrosis and subsequent termination in acute myeloblastic leu-
patients with myelofibrosis. Blood 109:1316, 2007. kaemia: Case report and review of the literature. Eur J Haematol 38:279, 1987.
478. Devine SM, Hoffman R, Verma A, et al: Allogeneic blood cell transplantation following 499. Chan ACL, Kwong Y-L, Lam CCK: Granulocytic sarcoma of megakaryoblastic differen-
reduced-intensity conditioning is effective therapy for older patients with myelofibrosis tiation complicating chronic idiopathic myelofibrosis. Hum Pathol 27:417, 1996.
with myeloid metaplasia. Blood 99:2255, 2002. 500. Barnes HM, Prchal JT, Scott CW: Extramedullary blast transformation in the central
479. Hessling J, Kroger N, Werner M, et al: Dose-reduced conditioning regimen followed by nervous system in idiopathic myelofibrosis. Am J Hematol 11:305, 1981.
allogeneic stem cell transplantation in patients with myelofibrosis with myeloid meta- 501. Polliack A, Prokocimer M, Matzner Y, et al: Lymphoblastic leukemic transformation
plasia. Br J Haematol 119:769, 2002. (lymphoblastic crisis) in myelofibrosis and myeloid metaplasia. Am J Hematol 9:211,
480. Merup M, Lazarevic V, Nahi H, et al: Different outcome of allogeneic transplantation 1980.
in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J 502. Yinon A, Kopolovic J, Dollberg L, Hershko C: Evolution of malignant lymphoma in
Haematol 135:367, 2006. agnogenic myeloid metaplasia. Oncology 45:373, 1988.
481. Greyz N, Miller WE, Andrey J, Masson J: Long-term remission of myelofibrosis fol- 503. Barosi G, Ambrosetti A, Centra A: Splenectomy and risk of blast transformation in
lowing nonmyeloablative allogenic peripheral blood progenitor cell transplantation in myelofibrosis with myeloid metaplasia. Blood 91:3630, 1998.
older age. Bone Marrow Transplant 34:833, 2004. 504. Huang J, Li CY, Mesa RA, et al: Risk factors for leukemic transformation in patients
482. Gupta V, Malone AK, Hari PN, et al: Reduced-intensity hematopoietic cell transplan- with primary myelofibrosis. Cancer 112:2726, 2008.
tation for patients with primary myelofibrosis: A cohort analysis from the center for 505. Shreiner DP: Spontaneous hematologic remission in agnogenic myeloid metaplasia.
international blood and marrow transplant research. Biol Blood Marrow Transplant Am J Med 60:1014, 1976.
20:89, 2014. 506. Rani MV, Shreiner DP: Spontaneous “remission” of agnogenic myeloid metaplasia and
483. Hoffman R, Prchal JT, Samuelson S, et al: Philadelphia chromosome-negative myelopro- termination in acute myeloid leukemia. Arch Intern Med 141:1481, 1981.
liferative disorders: Biology and treatment. Biol Blood Marrow Transplant 13(Suppl 1): 507. Vannucchi AM, Lasho TL, Guglielmelli P, et al: Mutations and prognosis in primary
64, 2007. myelofibrosis. Leukemia 27:1861, 2013.
484. Anderson JE, Tefferi A, Craig F, et al: Myeloablation and autologous peripheral blood 508. Guglielmelli P, Lasho TL, Rotunno G, et al: The number of prognostically detrimen-
stem cell rescue results in hematologic and clinical responses in patients with myeloid tal mutations and prognosis in primary myelofibrosis: An international study of
metaplasia with myelofibrosis. Blood 98:586, 2001. 797 patients. Leukemia 28:1804, 2014.
485. Visini G, Finelli C, Castelli U, et al: Myelofibrosis with myeloid metaplasia: Clinical and 509. Poletto V, Rosti V, Villani L, et al: A3669G polymorphism of glucocorticoid receptor is
haematological parameters predicting survival in a series of 133 patients. Br J Haematol a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity
75:4, 1990. and blast transformation. Blood 120:3112, 2012.
486. Cervantes F: Prognostic and current practice in treatment of myelofibrosis and myeloid 509A. Tefferi A, Lasho TL, Finke CM, et al: CALR vs JAK2 vs MPL-mutated or triple-negative
metaplasia: An update anno 2000. Pathol Biol (Paris) 49:148, 2001. myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 28:1472,
487. Mesa RA, Li C-Y, Schroeder G, Tefferi A: Clinical correlates of splenic histology and 2014.
splenic karyotype in myelofibrosis with myeloid metaplasia. Blood 97:3665, 2001. 510. Altura RA, Headv DR, Wang WC: Long-term survival of infants with idiopathic myel-
488. Kvasnicka HM, Thiele J, Regn C, et al: Prognostic impact of apoptosis and proliferation ofibrosis. Br J Haematol 109:459, 2000.
in idiopathic (primary) myelofibrosis. Ann Hematol 78:65, 1999. 511. Sah A, Minford A, Parapia LA: Spontaneous remission of juvenile idiopathic myelofi-
489. Elliott MA, Verstovsek S, Dingli D, et al: Monocytosis is an adverse prognostic factor brosis. Br J Haematol 112:1083, 2001.
for survival in younger patients with primary myelofibrosis. Leuk Res 31:1503, 2007.

Kaushansky_chapter 86_p1319-1340.indd 1339 9/18/15 10:24 AM